DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adagene Inc. Sponsored ADR (ADAG) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Reasons to Add The Cooper Companies (COO) to Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.
Inogen (INGN) Rises 127% Year to Date: What's Driving the Stock?
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for the Inogen (INGN) stock.
Glaukos (GKOS) Gains 63.5% YTD: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Alcon (ALC) Q2 Earnings Meet Estimates, Revenues Increase Y/Y
by Zacks Equity Research
Alcon (ALC) delivers impressive growth in Implantables and Contact Lenses in the second quarter of 2024.
Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
Why You Should Add HCA Healthcare (HCA) to Your Portfolio Now
by Zacks Equity Research
HCA Healthcare (HCA) remains well-poised for growth on growing emergency room visits, buyouts and solid cash flows.
GE HealthCare's (GEHC) Tie-Up to Boost Female Pelvic Healthcare
by Zacks Equity Research
GE HealthCare's (GEHC) latest collaboration is likely to equip clinicians with a toolset to deliver enhanced care to female patients and improve the patient experience.
Avantor (AVTR) Inks Deal to Optimize Portfolio, Reduce Debt
by Zacks Equity Research
Avantor's (AVTR) latest agreement is likely to enhance its focus on strategic growth opportunities and reduce its debt burden.
4 Stocks Trading Near 52-Week High With More Upside Potential
by Vasundhara Sawalka
Investors target stocks that have lately been on a bull run. Stocks like PPC, THC, DVA and UHS are seeing price strength and have a high chance of carrying the momentum forward.
Masimo (MASI) Gets New Suitors for Its Consumer Business Sale
by Zacks Equity Research
Masimo (MASI) receives unsolicited requests from multiple entities for acquiring its consumer business. The company already received a non-binding term sheet confirmation from a third party in May.
Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.
DaVita Inc. (DVA) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Accuray (ARAY) Q4 Earnings Lag Estimates, Gross Margin Shrinks
by Zacks Equity Research
Despite improving product sales, Accuray (ARAY) reports mixed fourth-quarter fiscal 2024 results.
Stereotaxis (STXS) Receives European Approval for GenesisX
by Zacks Equity Research
Stereotaxis (STXS) gains CE mark for GenesisX and plans to launch the system in 2025.
Labcorp (LH) Gains From New Collaborations Amid FX Issues
by Zacks Equity Research
Labcorp's (LH) Biopharma Laboratory Services business is benefiting from collaborations with leading pharmaceutical and biotechnology companies.
DaVita HealthCare (DVA) Is Up 0.56% in One Week: What You Should Know
by Zacks Equity Research
Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cardinal Health (CAH) Beats on Q4 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) fourth-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.
Reasons to Retain Veeva Systems (VEEV) in Your Portfolio Now
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock. However, data security threats and escalating costs are concerning.
Quest Diagnostics (DGX) Gains From Innovation, Customer Wins
by Zacks Equity Research
A key driver in Brain Health growth is Quest Diagnostics' (DGX) Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF Tests for diagnosing and monitoring.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Neuronetics (STIM) Q2 Loss Wider Than Expected, Revenues Fall Y/Y
by Zacks Equity Research
Neuronetics' (STIM) second-quarter 2024 top-line results reflect lower revenues from NeuroStar Advanced Therapy System and Treatment sessions.
Haemonetics (HAE) Q1 Earnings Miss Estimates, Gross Margin Rises
by Zacks Equity Research
Haemonetics' (HAE) earnings lag estimates in the first quarter of fiscal 2025. However, the company remains confident about its strategy for sustained profitable growth.